KOSDAQ - Delayed Quote KRW

Sinil Pharmaceutical Co., Ltd. (012790.KQ)

7,080.00 +20.00 (+0.28%)
At close: 3:30 PM GMT+9
Loading Chart for 012790.KQ
DELL
  • Previous Close 7,060.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 8,380.00
  • Volume 0
  • Avg. Volume 45,567
  • Market Cap (intraday) 81.842B
  • Beta (5Y Monthly) 1.52
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In addition, it is involved in the real estate rental services. The company was founded in 1971 and is headquartered in Chungju-si, South Korea.

www.sinilpharm.com

--

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Related News

Performance Overview: 012790.KQ

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

012790.KQ
8.17%
KOSPI Composite Index
0.77%

1-Year Return

012790.KQ
9.57%
KOSPI Composite Index
6.03%

3-Year Return

012790.KQ
52.90%
KOSPI Composite Index
15.89%

5-Year Return

012790.KQ
9.33%
KOSPI Composite Index
21.57%

Compare To: 012790.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 012790.KQ

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.30%

  • Return on Assets (ttm)

    5.92%

  • Return on Equity (ttm)

    10.57%

  • Revenue (ttm)

    89.14B

  • Net Income Avi to Common (ttm)

    13.64B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    23.42B

  • Total Debt/Equity (mrq)

    0.40%

  • Levered Free Cash Flow (ttm)

    -2.86B

Company Insights: 012790.KQ

People Also Watch